SEC Comment Letter 0000000000-24-002991 to Allogene Therapeutics, Inc. (ALLO) (CIK 0001737287) (ALLO)
Allogene Therapeutics, Inc. (ALLO) (CIK 0001737287)
Date: March 19, 2024 · CIK: 0001737287 · Accession: 0000000000-24-002991
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277951
Letter
United States securities and exchange commission logo March 19, 2024 David Chang, M.D., Ph.D. Chief Executive Officer Allogene Therapeutics, Inc. 210 East Grand Avenue South San Francisco, CA 94080 Re:Allogene Therapeutics, Inc. Registration Statement on Form S-3 Filed March 14, 2024 File No. 333-277951 Dear David Chang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Asa M. Henin, Esq.
Show Raw Text
United States securities and exchange commission logo
March 19, 2024
David Chang, M.D., Ph.D.
Chief Executive Officer
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, CA 94080
Re:Allogene Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 14, 2024
File No. 333-277951
Dear David Chang:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Asa M. Henin, Esq.